Breakthrough Medication in Unresponsive Palliative Care Patients: Indications, Practice, and Efficacy

Area of Science:

• Critical Care Medicine
• Pharmacology
• Patient Monitoring

Background:

• Assessing unresponsive patients' needs and responses to breakthrough medication relies on clinical and observational measures, but their alignment with patient experience is unclear.
• Understanding the true efficacy of breakthrough medications and patient comfort perception is crucial for optimizing care in critical settings.

Purpose of the Study:

• To determine the efficacy and effectiveness of breakthrough medication in unresponsive patients.
• To evaluate patient comfort perception by nurses and family members.
• To compare objective measures (BIS) with subjective assessments (RASS, PCS) of medication response.

Main Methods:

• Prospective study comparing Richmond Agitation-Sedation Scale (RASS), Patient Comfort Score (PCS), and Bispectral Index (BIS) after breakthrough medication.
• Evaluated effects of opioid vs. opioid + benzodiazepine regimens.
• Assessed synchronous nurse and family measurements of PCS.

Main Results:

• Breakthrough medication significantly reduced BIS, RASS, and PCS scores at 30 and 60 minutes post-administration (P < 0.0004).
• No significant difference in efficacy was found between opioid and opioid + benzodiazepine breakthroughs.
• Families reported significantly higher patient discomfort than nurses (P < 0.0004).

Conclusions:

• Breakthrough medication is effective in unresponsive patients, with observable effects starting at 30 minutes.
• Observational measures like RASS and PCS are valuable for assessing patient response to medication.
• Family assessments of patient comfort may offer a more sensitive perspective than nursing assessments.